Travere Therapeutics Inc Topline Interim Results from the Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy Corporate Call Transcript
Hello, and welcome to the Travere Therapeutics, Inc. top line interim results from the Phase III PROTECT study of sparsentan in IgA nephropathy. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Chris Cline. Please go ahead.
Thank you, Deb. Good morning, and thank you all for joining us on short notice today to talk about the top line interim results from our ongoing Phase III PROTECT study of sparsentan in IgA nephropathy. A copy of the press release announcing the results are available on the Investors section of our website.
Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Eric will be joined for the prepared remarks by Dr. Noah Rosenberg, our Chief Medical Officer; and Dr. Bill Rote, Senior Vice President of Research and Development, will join us for the Q&A session.
Before we begin, I would like to remind everyone that statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |